Clinical Investigations Branch (CIB)

The Clinical Investigations Branch (CIB) is responsible for:

• Scientific coordination and oversight of the NCI’s National Clinical Trials Network Program (NCTN)
• Organization of comprehensive programs of preliminary and definitive clinical trials of precision medicine, such as Lung-MAP, ALCHEMIST, NCI-MATCH, and a pediatric version of NCI- MATCH
• Organization of innovative treatment, single/multiple agent or combined modalities, for adult, adolescent, and pediatric populations
• Facilitation and organization of clinical research including surgical and radiation therapy, as well as chemo-, biologic- and immuno-therapies in the treatment of cancer
• Coordination with the extramural scientific community and other NCI programs, such as the Coordinating Center for Clinical Trials (CCCT), on identifying and prioritizing trials for disease-related research
• Coordination with other NCI programs regarding collection, banking, and use of clinical biospecimens in conjunction with validated data from clinical trials
• Collaboration with NCTN groups, consortia, cancer centers and other entities in the development/harmonization of research standards and methodologies
• Collaboration with international clinical trials organizations
• Oversight of pediatric drug development, from testing of novel agents through the Pediatric Preclinical Testing Consortium (PPTC) to clinical evaluations of novel agents by CIB-supported pediatric clinical trials organizations
• Coordination and oversight of the adult and pediatric brain tumor consortia
• Collaboration with the NCI Central Institutional Review Board (CIRB), which with one centralized review, enables investigators to enroll patients into NCTN trials significantly faster than when obtaining approval from a local IRB
• Cooperation with the Cancer Trials Support Unit (CTSU), which simplifies admittance to NCTN trials for qualified clinical sites and supports the conduct of those clinical trials